Ataluren
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Aug 31, 2015 → Jun 2, 2017
NCT ID
NCT02456103About Ataluren
Ataluren is a phase 3 stage product being developed by PTC Therapeutics for Cystic Fibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02456103. Target conditions include Cystic Fibrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04336826 | Phase 2 | Completed |
| NCT03796637 | Phase 2 | Completed |
| NCT04117880 | Phase 2 | Withdrawn |
| NCT03648827 | Phase 2 | Completed |
| NCT02819557 | Phase 2 | Completed |
| NCT02456103 | Phase 3 | Terminated |
| NCT02107859 | Phase 3 | Terminated |
| NCT02090959 | Phase 3 | Terminated |
| NCT01557400 | Phase 3 | Completed |
| NCT01247207 | Phase 3 | Completed |
| NCT01140451 | Phase 3 | Completed |
| NCT00458341 | Phase 2 | Completed |
| NCT00237380 | Phase 2 | Completed |
Competing Products
20 competing products in Cystic Fibrosis